Identiv (NASDAQ:INVE) reported quarterly sales of $29.00 million which beat the analyst consensus estimate of $27.87 million by 4.06 percent. This is a 1.70 percent increase over sales of $28.52 million the same period last year.
Ascendis Pharma’s Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial
Ascendis Pharma A/S (NASDAQ: ASND) released topline results from Phase 3 foresiGHt trial to compare the efficacy and safety of TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth hormone, somatropin) in adults with growth
